Molecular biomarkers for advanced renal cell carcinoma: Implications for prognosis and therapy

Urologic Oncology: Seminars and Original Investigations

Volumn 28, Issue 2, 2010, Pages 157-163

  Kim, Hyo Song ^a   Kim, Won Seog ^a   Park, Se Hoon ^a   Jung, Chul Won ^a   Choi, Han Yong ^b   Lee, Hyun Moo ^b   Jeon, Seong Soo ^b   Ha, Hongil ^c   Hwang, In Gyu ^d   Lee, Seungkoo ^e   Lim, Ho Yeong ^a  

^a Samsung Medical Center   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c National Institute of Scientific Investigation   (South Korea)

^d Yangsan Neuropsychiatric Hospital   (South Korea)

^e Kangwon National University   (South Korea)

Author keywords

Carbonic anhydrase IX; Cyclooxygenase 2; Renal cell carcinoma; Vascular endothelial growth factor

Indexed keywords

CARBONATE DEHYDRATASE IX; CYCLOOXYGENASE 2; PARAFFIN; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CELL TYPE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION;

ADULT; AGED; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77249169816     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2008.08.002     Document Type: Article

References (33)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Rouviere O., Bouvier R., Negrier S., et al. Nonmetastatic renal-cell carcinoma: Is it really possible to define rational guidelines for post-treatment follow-up?. Nat Clin Pract Oncol 3 (2006) 200-213
3. Dutcher J.P., Fisher R.I., Weiss G., et al. Outpatient subcutaneous interleukin-2 and interferon-{white small square} for metastatic renal cell cancer: Five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 3 (1997) 157-162
4. Negrier S., Escudier B., Lasset C., et al. Recombinant human interleukin-2, recombinant human interferon {white small square}-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 338 (1998) 1272-1278
5. Atkins M., Regan M., McDermott D., et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11 (2005) 3714-3721
6. Bui M.H., Seligson D., Han K.R., et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res 9 (2003) 802-811
7. Hara S., Kondo Y., Matsuzawa I., et al. Expression of cycloxygenase-2 in human bladder and renal cell carcinoma. Adv Exp Med Biol 507 (2002) 123-126
8. Miyata Y., Koga S., Kanda S., et al. Expression of cyclooxygenase-2 in renal cell carcinoma: Correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res 9 (2003) 1741-1749
9. Rini B.I., Weinberg V., Dunlap S., et al. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon-α therapy in metastatic renal cell carcinoma. Cancer 106 (2006) 566-575
10. Yilmazer D., Han U., and Onal B. A comparison of the vascular density of VEGF expression with microvascular density determined with CD34 and CD31 staining and conventional prognostic markers in renal cell carcinoma. Int Urol Nephrol 39 (2007) 691-698
11. Royal R.E., Steinberg S.M., Krouse R.S., et al. Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J Sci Am 2 (1996) 91-98
12. Figlin R., Gitlitz B., Franklin J., et al. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: An analysis of 203 consecutively treated patients. Cancer J Sci Am 3 Suppl 1 (1997) S92-S97
13. Leibovich B.C., Han K.R., Bui M.H., et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: A stratification tool for prospective clinical trials. Cancer 98 (2003) 2566-2575
14. Driessen A., Landuyt W., Pastorekova S., et al. Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann Surg 243 (2006) 334-340
15. Hedley D., Pintilie M., Woo J., et al. Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. Clin Cancer Res 9 (2003) 5666-5674
16. Liao S.Y., Aurelio O.N., Jan K., et al. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res 57 (1997) 2827-2831
17. Uemura H., Nakagawa Y., Yoshida K., et al. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 81 (1999) 741-746
18. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon-α, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
19. Pastorek J., Pastorekova S., Callebaut I., et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 9 (1994) 2877-2888
20. Ivanov S., Liao S.Y., Ivanova A., et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158 (2001) 905-919
21. Wykoff C.C., Pugh C.W., Maxwell P.H., et al. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumor suppressor by mRNA differential expression profiling. Oncogene 19 (2000) 6297-6305
22. Olive P.L., Aquino-Parsons C., MacPhail S.H., et al. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res 61 (2001) 8924-8929
23. Wykoff C.C., Beasley N.J., Watson P.H., et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60 (2000) 7075-7083
24. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 37 (2000) 431-502
25. Ohtawa Y., Naomoto Y., Shirakawa Y., et al. The close relationship between heparinase and cyclo-oxygenase-2 expressions in signet-ring cell carcinoma of the stomach. Hum Pathol 37 (2006) 1145-1152
26. Chen Q., Shinohara N., Abe T., et al. Significance of COX-2 expression in human renal cell carcinoma cell lines. Int J Cancer 108 (2004) 825-832
27. Kokawa A., Kondo H., Gotoda T., et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 91 (2001) 333-338
28. Jain R.K. Tumor angiogenesis and accessibility: Role of vascular endothelial growth factor. Semin Oncol 29 (2002) 3-9
29. Jacobsen J., Rasmuson T., Grankvist K., et al. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 163 (2000) 343-347
30. Chang S.G., Jeon S.H., Lee S.J., et al. Clinical significance of urinary vascular endothelial growth factor and microvessel density in patients with renal cell carcinoma. Urology 58 (2001) 904-908
31. Slaton J.W., Inoue K., Perrotte P., et al. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol 158 (2001) 735-743
32. Tomisawa M., Tokunaga T., Oshika Y., et al. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumor stage and vascularization in renal cell carcinoma. Eur J Cancer 35 (1999) 133-137
33. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomized, double-blind Phase III trial. Lancet 370 (2007) 2103-2111